Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2010-05-27
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT01132118
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Amer Zureikat
- Target Recruit Count
- 35
- Registration Number
- NCT01128296
- Locations
- 🇺🇸
UPCI/UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
Hydroxychloroquine Efficacy in Chronic Urticaria
- Conditions
- Interventions
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Vanderbilt University
- Registration Number
- NCT01073852
Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2010-07-30
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 83
- Registration Number
- NCT01067417
Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT01026844
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2023-02-13
- Target Recruit Count
- 72
- Registration Number
- NCT01023737
- Locations
- 🇺🇸
Cancer Therapy & Research Center University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 38
- Registration Number
- NCT01006369
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cooper Hospital/University Medical Center, Camden, New Jersey, United States
🇺🇸Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT00977470
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 20
- Registration Number
- NCT00962845
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
- Conditions
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT00909831
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.